← Back to headlines
Novo Downgraded by J.P. Morgan as Obesity Drug Trails Lilly’s Zepbound
Novo has been downgraded by J.P. Morgan, as its next-generation obesity drug is reportedly trailing behind Lilly’s Zepbound in market performance.
24 Feb, 17:50 — 24 Feb, 17:50
ℹOnly 1 source covers this story
